Dr. Bin Zhang and his team at Northwestern Medicine found a reason why a promising cancer drug seemed to stop working for some patients — and a way to fix it.
The drug is called olaparib, a "targeted therapy" that helps attack advanced prostate cancer. It works especially well for the roughly 30% of patients whose cancer cells have lost the ability to repair broken DNA. But earlier studies showed that adding another type of drug, called an immune checkpoint inhibitor, barely helped. Zhang wanted to know why.
The answer, published in The Journal of Clinical Investigation, was a surprise. When olaparib damaged the cancer cells' DNA, the cells fought back by turning up a molecule called CD73. CD73 acts like a shield: it pumps out a chemical that silences the body's T-cells — the immune soldiers that are supposed to hunt down and destroy cancer. In other words, the very drug meant to weaken the cancer accidentally helped it hide.
"That's the key insight," the researchers explained. By figuring out exactly which chemical pathways produce that CD73 shield, the team could figure out how to remove it.
So Zhang's team tested a new combination in mice with prostate cancer. Instead of just giving olaparib, they paired it with a "CD73 blockade" — a treatment that strips away the shield. The results were dramatic. Tumors grew more slowly, far more T-cells flooded into the cancer, and the immune system's frontline fighters (called CD8+ T-cells) got stronger and more effective.
What makes this especially exciting is who it could help. Most patients with metastatic castration-resistant prostate cancer — an advanced form that has spread beyond the prostate and stopped responding to hormone therapy — do not have that broken-DNA trait. This new combination worked in mice even without it, which means it may reach many more patients.
This disease carries a heavy toll. It is a leading cause of cancer-related death in men worldwide, and the average life expectancy after diagnosis is about three years. Any strategy that can extend or improve that timeline matters enormously.
This is still early science. The findings come from mouse models, not human trials, and much work remains before this reaches patients. But the study pinpoints a real, "therapeutically actionable" target — a switch that doctors might one day flip to make an effective drug even better.
Zhang, who holds the Johanna Dobe Professorship of Cancer Immunology, put it simply: "We identified a new combination therapy strategy to overcome immune-cold tumors and sensitize them to immunotherapy." For men facing one of the toughest battles in cancer medicine, that is a spark of real hope.